57 related articles for article (PubMed ID: 24316937)
1. Identification of novel inhibitors against Mycobacterium tuberculosis L-alanine dehydrogenase (MTB-AlaDH) through structure-based virtual screening.
Saxena S; Devi PB; Soni V; Yogeeswari P; Sriram D
J Mol Graph Model; 2014 Feb; 47():37-43. PubMed ID: 24316937
[TBL] [Abstract][Full Text] [Related]
2. Virtual Screening of potential drug-like inhibitors against Lysine/DAP pathway of Mycobacterium tuberculosis.
Garg A; Tewari R; Raghava GP
BMC Bioinformatics; 2010 Jan; 11 Suppl 1(Suppl 1):S53. PubMed ID: 20122228
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential non-nucleoside MraY inhibitors for tuberculosis chemotherapy using structure-based virtual screening.
Pandey P; Chatterjee S; Berida T; Doerksen RJ; Roy S
J Biomol Struct Dyn; 2022 Jul; 40(11):4832-4849. PubMed ID: 33353500
[TBL] [Abstract][Full Text] [Related]
4. Overexpression, purification, crystallization and preliminary X-ray analysis of Rv2780 from Mycobacterium tuberculosis H37Rv.
Tripathi SM; Ramachandran R
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2008 May; 64(Pt 5):367-70. PubMed ID: 18453703
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Mycobacterium tuberculosis dihydrodipicolinate synthase by alpha-ketopimelic acid and its other structural analogues.
Shrivastava P; Navratna V; Silla Y; Dewangan RP; Pramanik A; Chaudhary S; Rayasam G; Kumar A; Gopal B; Ramachandran S
Sci Rep; 2016 Aug; 6():30827. PubMed ID: 27501775
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore based virtual screening & molecular docking approach for identification of mycobacterial membrane protein large 3 (MmpL3) inhibitors.
Dhulap A; Banerjee P
J Biomol Struct Dyn; 2023 Dec; 41(20):11062-11077. PubMed ID: 36571432
[TBL] [Abstract][Full Text] [Related]
7. Ligand-based pharmacophore modelling, virtual screening and docking studies to identify potential compounds against FtsZ of Mycobacterium tuberculosis.
Suresh M; Naicker K; Solanki J; Ezirim SA; Turcio R; Tochukwu IG; Lakhdari K; Attah EI
Indian J Tuberc; 2023 Oct; 70(4):430-444. PubMed ID: 37968049
[TBL] [Abstract][Full Text] [Related]
8. In silico screening for novel inhibitors of DNA polymerase III alpha subunit of Mycobacterium tuberculosis (MtbDnaE2, H37Rv).
Jadaun A; Sudhakar D R; Subbarao N; Dixit A
PLoS One; 2015; 10(3):e0119760. PubMed ID: 25811866
[TBL] [Abstract][Full Text] [Related]
9. Novel scaffolds targeting Mycobacterium tuberculosis plasma membrane Ca
A Varon H; Santos P; Lopez-Vallejo F; Y Soto C
Bioorg Chem; 2023 Sep; 138():106648. PubMed ID: 37315451
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate recognition by RpfB from Mycobacterium tuberculosis unveiled by crystallographic and molecular dynamics analyses.
Squeglia F; Romano M; Ruggiero A; Vitagliano L; De Simone A; Berisio R
Biophys J; 2013 Jun; 104(11):2530-9. PubMed ID: 23746526
[TBL] [Abstract][Full Text] [Related]
11. Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-d-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC).
Sivendran S; Jones V; Sun D; Wang Y; Grzegorzewicz AE; Scherman MS; Napper AD; McCammon JA; Lee RE; Diamond SL; McNeil M
Bioorg Med Chem; 2010 Jan; 18(2):896-908. PubMed ID: 19969466
[TBL] [Abstract][Full Text] [Related]
12. Shape-Based Virtual Screening of a Billion-Compound Library Identifies Mycobacterial Lipoamide Dehydrogenase Inhibitors.
Michino M; Beautrait A; Boyles NA; Nadupalli A; Dementiev A; Sun S; Ginn J; Baxt L; Suto R; Bryk R; Jerome SV; Huggins DJ; Vendome J
ACS Bio Med Chem Au; 2023 Dec; 3(6):507-515. PubMed ID: 38144256
[TBL] [Abstract][Full Text] [Related]
13. Hybrid Dynamic Pharmacophore Models as Effective Tools to Identify Novel Chemotypes for Anti-TB Inhibitor Design: A Case Study With Mtb-DapB.
Choudhury C; Bhardwaj A
Front Chem; 2020; 8():596412. PubMed ID: 33425853
[TBL] [Abstract][Full Text] [Related]
14. Two different alanine dehydrogenases from Geobacillus kaustophilus: Their biochemical characteristics and differential expression in vegetative cells and spores.
Maeno M; Ohmori T; Nukada D; Sakuraba H; Satomura T; Ohshima T
Biochim Biophys Acta Proteins Proteom; 2023 Jul; 1871(4):140904. PubMed ID: 36918121
[TBL] [Abstract][Full Text] [Related]
15.
Pathirage R; Favrot L; Petit C; Yamsek M; Singh S; Mallareddy JR; Rana S; Natarajan A; Ronning DR
RSC Med Chem; 2023 May; 14(5):921-933. PubMed ID: 37252106
[TBL] [Abstract][Full Text] [Related]
16. The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis.
Evans JC; Mizrahi V
Front Microbiol; 2015; 6():812. PubMed ID: 26300875
[TBL] [Abstract][Full Text] [Related]
17. Insilico analysis and molecular docking of resuscitation promoting factor B (RpfB) protein of Mycobacterium tuberculosis.
Mylliemngap BJ; Borthakur A; Velmurugan D; Bhattacharjee A
Bioinformation; 2012; 8(14):646-51. PubMed ID: 23055604
[TBL] [Abstract][Full Text] [Related]
18. Predictive Power of In Silico Approach to Evaluate Chemicals against
Timo GO; Reis RSSVD; Melo AF; Costa TVL; Magalhães PO; Homem-de-Mello M
Pharmaceuticals (Basel); 2019 Sep; 12(3):. PubMed ID: 31527425
[No Abstract] [Full Text] [Related]
19. Expression, Purification, and Bioinformatic Prediction of Mycobacterium tuberculosis Rv0439c as a Potential NADP
Tang W; Gui C; Zhang T
Mol Biotechnol; 2023 Nov; ():. PubMed ID: 37989944
[TBL] [Abstract][Full Text] [Related]
20. Computational fragment-based drug design of potential Glo-I inhibitors.
Bibars RS; Al-Balas QA
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2301758. PubMed ID: 38247330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
